SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

SICRAS-MAINAR, Antoni; NAVARRO-ARTIEDA, Ruth  and  IBANEZ-NOLLA, Jordi. Uso de recursos y costos asociados a las fracturas en mujeres españolas. Rev Peru Med Exp Salud Publica [online]. 2012, vol.29, n.3, pp.350-356. ISSN 1726-4642.

    1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785-95. [ Links ]

    2. Muoz-Torres M, Alonso G, Mezquita-Raya P. Prevencin y tratamiento de la osteoporosis. Endocrinol Nutr. 2003;50:1-7. [ Links ]

    3. World Health Organization (WHO). Assessments of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Geneva: WHO; 1994. [ Links ]

    4. Grupo de Trabajo de la Sociedad Espaola de Investigaciones Oseas y Metabolismo Mineral. Osteoporosis posmenopusica. Gua de prctica clnica. Rev Clin Esp. 2003;203(10):496-506. [ Links ]

    5. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726-33. [ Links ]

    6. Lespessailles E, Cott FE, Roux C, Fardellone P, Mercier F, Gaudin AF. Prevalence and features of osteoporosis in the French general population: the Instant study. Joint Bone Spine. 2009;76(4):394-400. [ Links ]

    7. Cheng H, Gary LC, Curtis JR, Saag KG, Kilgore ML, Morrisey MA, et al. Estimated prevalence and patterns of presumed osteoporosis among older Americans based on Medicare data. Osteoporos Int. 2009;20(9):1507-15. [ Links ]

    8. Recker R, Lappe J, Davies KM, Heaney R. Bone remodelling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res. 2004;19(10):1628-33. [ Links ]

    9. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int. 2005;16(3):229-38. [ Links ]

    10. Naves M, Daz-Lpez JB, Gmez C, Rodrguez-Rebollar A, Cannata-Anda JB. Determinants of incidence of osteoporotic fractures in the female Spanish population older than 50. Osteoporos Int. 2005;16(12):2013-7. [ Links ]

    11. Sosa M, Saavedra P; Grupo de trabajo en osteoporosis de la Sociedad Espaola de Medicina Interna (SEMI). Prevalence of vertebral fractures in hip fracture patients. Rev Clin Esp. 2007;207(9):464-8. [ Links ]

    12. Panel de Expertos de la Sociedad Espaola de Reumatologa. Documento de la Sociedad Espaola de Reumatologa sobre la osteoporosis posmenopusica. Rev Esp Reumatol. 2001;28:148-53. [ Links ]

    13. Sanders KM, Nicholson GC, Watts JJ, Pasco JA, Henry MJ, Kotowicz MA, et al. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone. 2006;38(5):694-700. [ Links ]

    14. Vestergaard P, Rejnmark L, Mosekilde L. Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos Int. 2007;18(12):1583-93. [ Links ]

    15. Marn F, Gonzlez-Macas J, Moya R, Onrubia C, Cancelo C, Alvarez S, et al. Fractura no vertebral por fragilidad en una cohorte de 5.201 mujeres de 65 o ms aos durante tres aos de seguimiento. Med Clin (Barc). 2006;127:401-4. [ Links ]

    16. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285(3):320-3. [ Links ]

    17. Strm O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, et al. Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop. 2008;79(2):269-80. [ Links ]

    18. Schousboe JT. Cost-effectiveness modeling research of pharmacologic therapy to prevent osteoporosis-related fractures. Curr Rheumatol Rep. 2007;9(1):50-6. [ Links ]

    19. Majumdar SR, Lier DA, Beaupre LA, Hanley DA, Maksymowych WP, Juby AG, et al. Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial. Arch Intern Med. 2009;169(1):25-31. [ Links ]

    20. Christensen L, Iqbal S, Macarios D, Badamgarav E, Harley C. Cost of fractures commonly associated with osteoporosis in a managed-care population. J Med Econ. 2010;13(2):302-13. [ Links ]

    21. Lamberts H, Wood M, Hofmans-Okkes IM, editors. The International Classification of Primary Care in the European Community: with a multi-language layer. Oxford: Oxford University Press; 1993. [ Links ]

    22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. [ Links ]

    23. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed?. BMJ. 2000;320(7243):1197-200. [ Links ]

    24. Meltzer M. Introduction to Health Economics for Physicians. The Lancet. 2001;358(9286):993-8. [ Links ]

    25. Sosa M, Gmez de Tejada MJ. Epidemiologa de la fractura vertebral. En: Daz Curiel M, editor. La fractura vertebral en la prctica clnica. Marid: FHOEMO; 2005. p. 1-6. [ Links ]

    26. Briot K, Cortet B, Trmollires F, Sutter B, Thomas T, Roux C, et al. Male osteoporosis: diagnosis and fracture risk evaluation. Joint Bone Spine. 2009;76(2):129-33. [ Links ]

    27. Boonen S, Singer AJ. Osteoporosis management: impact of fracture type on cost and quality of life in patients at risk for fracture I. Curr Med Res Opin. 2008;24(6):1781-8. [ Links ]

    28. Gabriel SE, Tosteson AN, Leibson CL, Crowson CS, Pond GR, Hammond CS, et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 2002;13(4):323-30. [ Links ]

    29. Desai SS, Duncan BS, Sloan AS. The cost of treating osteoporosis in a managed health care organization. J Manag Care Pharm. 2003;9(2):142-9. [ Links ]